Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.

S'inscrire

CMPX Compass Therapeutics Inc

0,885049

-0,06045 (-6,39%)

Dernière mise à jour : 19:20:54

Retardé de 15 minutes

Annual Report to Security Holders (ars)

This regulatory filing also includes additional resources:
ny20008153x3_ars.pdf

Compass Therapeutics (NASDAQ:CMPX)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024

Plus de graphiques de la Bourse Compass Therapeutics

Compass Therapeutics (NASDAQ:CMPX)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024

Plus de graphiques de la Bourse Compass Therapeutics

Actualités Compass Therapeutics, Inc.

Form 8-K - Current report
Lundi 17 Juin 2024 ( il y a 2 semaines) • Edgar (US Regulatory)

Compass Therapeutics to Participate in the Jefferies Global Healthcare Conference
Jeudi 30 Mai 2024 ( il y a 1 mois) • GlobeNewswire Inc.

Compass Therapeutics Announces CEO Transition
Mardi 28 Mai 2024 ( il y a 1 mois) • GlobeNewswire Inc.

Form 8-K - Current report
Mardi 28 Mai 2024 ( il y a 1 mois) • Edgar (US Regulatory)

Compass Therapeutics to Present Phase 1 Data for CTX-471, A Novel CD137 Agonist Antibody, Demonstrating Anti-Tumor Activity in Patients Who Have Progressed on Approved PD-1 or PD-L1 Inhibitors at the American Society of Clinical Oncology (ASCO) Annual Meet
Jeudi 23 Mai 2024 ( il y a 1 mois) • GlobeNewswire Inc.

Compass Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
Mardi 14 Mai 2024 ( il y a 2 mois) • GlobeNewswire Inc.

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Lundi 13 Mai 2024 ( il y a 2 mois) • Edgar (US Regulatory)

Form 8-K - Current report
Lundi 13 Mai 2024 ( il y a 2 mois) • Edgar (US Regulatory)

Compass Therapeutics Reports 2024 First Quarter Financial Results and Provides Corporate Update
Lundi 13 Mai 2024 ( il y a 2 mois) • GlobeNewswire Inc.

Compass Therapeutics Receives FDA Fast Track Designation for the Investigation of CTX-009 in Combination with Paclitaxel for the Treatment of Patients with Metastatic or Locally Advanced Biliary Tract Tumors That Have Been Previously Treated
Jeudi 25 Avril 2024 ( il y a 2 mois) • GlobeNewswire Inc.

Compass Therapeutics Announces First Patient Dosed in the Phase 1 Study of CTX-8371 in Patients with Solid Tumors
Mardi 16 Avril 2024 ( il y a 3 mois) • GlobeNewswire Inc.

Compass Therapeutics Announces Poster Presentations at the Cholangiocarcinoma Foundation 2024 Annual Conference
Vendredi 12 Avril 2024 ( il y a 3 mois) • GlobeNewswire Inc.

Plus d'articles sur Compass Therapeutics, Inc.

Delayed Upgrade Clock

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales